» Articles » PMID: 38856821

CD4 Nadir and Neurocognitive Trajectories in People Living with HIV

Overview
Journal J Neurovirol
Publisher Springer
Specialties Microbiology
Neurology
Date 2024 Jun 10
PMID 38856821
Authors
Affiliations
Soon will be listed here.
Abstract

Human immunodeficiency virus-associated neurocognitive disorders persist in the combination antiretroviral therapy era. CD4 nadir is a well-established predictor of cognition cross-sectionally, but its impact on longitudinal neurocognitive (NC) trajectories is unclear. The few studies on this topic examined trajectories of global cognition, rather than specific NC domains. The current study examined CD4 nadir in relation to domain-specific NC decline. 132 HIV + adults from the Temple/Drexel Comprehensive NeuroHIV Center, Clinical and Translational Research Support Core Cohort were administered comprehensive NC assessments longitudinally, with last visit occurring an average of 12 years after CD4 nadir. Linear mixed models were used to examine CD4 nadir in relation to longitudinal NC trajectories in three empirically identified NC domains: speed/executive function (S/EF), visuospatial memory (VM), and verbal fluency (VF). CD4 nadir was associated with change in VF (p = 0.020), but not with S/EF or VM. Specifically, those with CD4 nadir < 200 demonstrated increasing VF over time (p = .002), whereas those with CD4 nadir > 200 demonstrated stable VF (p = .568), though these differing trajectories may partly reflect regression to the mean or differential practice effect. CD4 dynamics over time were analyzed as potential mechanisms for the identified associations, with mixed findings. While low CD4 nadir has been associated with weaker neurocognition among people living with HIV, the results of this study suggest that low CD4 nadir is not associated with ongoing decline a decade later. Nadir-related deficits in VF may be stable or even improve over time, possibly reflecting the beneficial cognitive effects of long-term treatment and immune reconstitution.

Citing Articles

Evaluation of Cognitive Functions in People Living with HIV Before and After COVID-19 Infection.

Basoulis D, Mastrogianni E, Eliadi I, Platakis N, Platis D, Psichogiou M Viruses. 2025; 17(1.

PMID: 39861924 PMC: 11769327. DOI: 10.3390/v17010135.


Anticholinergic and sedative medication use in persons with HIV: defining the evidence for risks on cognition.

Goodkin K, Winston A, Martinez E, Paul R AIDS. 2024; 38(13):1885-1887.

PMID: 39325004 PMC: 11749427. DOI: 10.1097/QAD.0000000000003994.

References
1.
Goodkin K, Miller E, Cox C, Reynolds S, Becker J, Martin E . Effect of ageing on neurocognitive function by stage of HIV infection: evidence from the Multicenter AIDS Cohort Study. Lancet HIV. 2017; 4(9):e411-e422. PMC: 5753579. DOI: 10.1016/S2352-3018(17)30098-X. View

2.
Sacktor N, Skolasky R, Seaberg E, Munro C, Becker J, Martin E . Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology. 2016; 86(4):334-40. PMC: 4776086. DOI: 10.1212/WNL.0000000000002277. View

3.
Bernal B, Ardila A, Rosselli M . Broca's area network in language function: a pooling-data connectivity study. Front Psychol. 2015; 6:687. PMC: 4440904. DOI: 10.3389/fpsyg.2015.00687. View

4.
Green S, Kong V, Laing G, Bruce J, Odendaal J, Sartorius B . The effect of stage of HIV disease as determined by CD4 count on clinical outcomes of surgical sepsis in South Africa. Ann R Coll Surg Engl. 2017; 99(6):459-463. PMC: 5696975. DOI: 10.1308/rcsann.2017.0057. View

5.
Maassen G . The standard error in the Jacobson and Truax Reliable Change Index: the classical approach to the assessment of reliable change. J Int Neuropsychol Soc. 2005; 10(6):888-93. DOI: 10.1017/s1355617704106097. View